Barcelona, Spain, and New Haven, Connecticut, United States, November 19, 2026
Biohaven Ltd. has announced encouraging clinical findings from its ongoing Phase 1 study of BHV-1530, an investigational, potentially first-in-class fibroblast growth factor receptor 3 (FGFR3)-directed antibody-drug conjugate (ADC) incorporating the company’s proprietary topoisomerase I (TopoIx) payload. The findings were presented during an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain. The preliminary results demonstrated tumour reductions and partial responses in patients with advanced solid tumours carrying activating FGFR3 alterations, particularly urothelial cancer and human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC). As of the October 19, 2026 data cutoff, 30 patients had received BHV-1530 monotherapy at doses ranging from 1.0 to 12.0 mg/kg every three weeks, with dose escalation ongoing. Among the 10 efficacy-evaluable patients with activating FGFR3 alterations treated at doses of 3.3 mg/kg or higher, nine experienced tumour reductions and six achieved partial responses, including confirmed or unconfirmed responses assessed by investigators using RECIST version 1.1 criteria. All six responders remained on treatment at the data cutoff, with some continuing therapy for more than six months. These findings provide an early clinical signal for a new targeted treatment strategy in cancers with limited options following progression on existing therapies.
BHV-1530 Demonstrates Responses in Advanced Cancers
The clinical activity was observed across two important cancer types. Among five patients with FGFR3-altered urothelial cancer, three achieved partial responses, despite all patients in this group having previously progressed on enfortumab vedotin plus pembrolizumab. One responding patient had also received an earlier FGFR inhibitor, highlighting the potential relevance of BHV-1530 in a setting where resistance to existing treatments can be a significant challenge. In the HPV-positive HNSCC group, all three patients with FGFR3-altered tumours achieved partial responses. One particularly notable case involved a patient with metastatic HPV-positive head and neck cancer carrying an FGFR3 S249C mutation who had received four previous lines of treatment, including chemoradiation, platinum-based chemotherapy and immunotherapy. This patient achieved a confirmed partial response, with a 67% reduction in target lesions by Week 6, which deepened to 86% by Week 24. The patient remained on treatment beyond six months without reported treatment-related adverse events at the data cutoff. Biohaven stated that responses were observed in tumours containing both FGFR3 mutations and gene fusions. These results are preliminary and come from a small, early-phase patient population; larger clinical studies will be needed to establish the treatment’s efficacy and determine which patients may benefit most.
Proprietary ADC Technology Offers a Different FGFR3 Approach
BHV-1530 is designed to use a targeted drug-delivery mechanism rather than directly inhibit FGFR kinase activity. The investigational ADC binds to FGFR3 on the surface of tumour cells, allowing the complex to be internalised and its proprietary TopoIx payload released inside the cell. The payload is intended to disrupt DNA-related processes and promote cancer-cell death. Unlike conventional FGFR tyrosine kinase inhibitors, which block signalling activity and may affect multiple FGFR family members, BHV-1530 is designed to selectively target FGFR3. Preclinical studies reported no detectable binding to FGFR1, FGFR2 or FGFR4. This approach may offer an alternative for patients whose tumours have developed resistance to kinase inhibitors or who cannot tolerate certain class-related toxicities. FGFR3 alterations and overexpression are frequently observed in urothelial cancer and are also associated with other solid tumours, making the receptor an important target for oncology drug development.
Early Safety Findings and Planned Clinical Development
Across all 30 patients treated in the Phase 1 study, BHV-1530 was reported to be generally well tolerated, with no dose-limiting toxicities, treatment-related serious adverse events or treatment-related deaths. The most frequently reported treatment-related adverse events were nausea, affecting 43% of patients, and fatigue, affecting 37%; all were Grade 1 or Grade 2. The company also reported no cases of hyperphosphatemia, nail dystrophy, central serous retinopathy or interstitial lung disease. Pharmacokinetic findings indicated that free payload exposure was below 1% of ADC exposure, while the observed half-life of seven to 14 days supported the every-three-week dosing schedule. Following a recent Type C meeting with the U.S. Food and Drug Administration (FDA), Biohaven plans to initiate a pivotal study in FGFR3-altered tumours, beginning with urothelial cancer, as early as the first half of 2027. The company is also evaluating BHV-1530 in combination with the anti-PD-1 antibody cemiplimab. Although the early findings are promising, BHV-1530 remains investigational and will require further clinical evaluation and regulatory review before any potential approval.
Source: Biohaven press release



